Diabetic Gastroparesis Pipeline Review H1 2019: Therapeutic Assessment of 8 Companies & 10 Drug Profiles – ResearchAndMarkets.com

BusinessWire

6 years ago

DUBLIN–(BUSINESS WIRE)–The “Diabetic
Gastroparesis – Pipeline Review, H1 2019” drug pipelines has
been added to ResearchAndMarkets.com’s offering.

Diabetic Gastroparesis – Pipeline Review, H1 2019, provides an overview
of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape.

This latest pipeline guide Diabetic Gastroparesis – Pipeline Review, H1
2019, provides comprehensive information on the therapeutics under
development for Diabetic Gastroparesis (Gastrointestinal), complete with
analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.

The Diabetic Gastroparesis (Gastrointestinal) pipeline guide also
reviews of key players involved in therapeutic development for Diabetic
Gastroparesis and features dormant and discontinued projects. The guide
covers therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in Pre-Registration,
Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 4, 2 and 1
respectively.

Diabetic Gastroparesis (Gastrointestinal) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Scope:

The pipeline guide provides a snapshot of the global therapeutic
landscape of Diabetic Gastroparesis (Gastrointestinal).
The pipeline guide reviews pipeline therapeutics for Diabetic
Gastroparesis (Gastrointestinal) by companies and
universities/research institutes based on information derived from
company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and
undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing
and collaboration details, R&D brief, MoA & other developmental
activities.
The pipeline guide reviews key companies involved in Diabetic
Gastroparesis (Gastrointestinal) therapeutics and enlists all their
major and minor projects.
The pipeline guide evaluates Diabetic Gastroparesis (Gastrointestinal)
therapeutics based on mechanism of action (MoA), drug target, route of
administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued
pipeline projects.
The pipeline guide reviews latest news related to pipeline
therapeutics for Diabetic Gastroparesis (Gastrointestinal)

Key Topics Covered:

Diabetic Gastroparesis – Overview

Diabetic Gastroparesis – Therapeutics Development

Pipeline Overview
Pipeline by Companies
Products under Development by Companies

Diabetic Gastroparesis – Therapeutics Assessment

Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

Diabetic Gastroparesis – Companies Involved in Therapeutics Development

AlfaSigma SpA
Allergan Plc
Censa Pharmaceuticals Inc
ETX Pharma Inc
Evoke Pharma Inc
Johnson & Johnson
Takeda Pharmaceutical Co Ltd
Vanda Pharmaceuticals Inc

Diabetic Gastroparesis – Drug Profiles

CNSA-001 – Drug Profile
ETX-101 – Drug Profile
ETX-301 – Drug Profile
metoclopramide – Drug Profile
prucalopride succinate – Drug Profile
relamorelin – Drug Profile
renzapride – Drug Profile
TAK-906 – Drug Profile
tradipitant – Drug Profile
velusetrag – Drug Profile

Share this: